ReviewPsychopharmacology2021
Mechanism and therapeutic strategies of depression after myocardial infarction.
Review in Psychopharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 2 syntheses or guidelines pooled it, 34 citations in OpenAlex.
- Cardiovascular diseases and depression: A meta-analysis and Mendelian randomization analysis.Molecular psychiatry · 2025Pooled it
- Potential therapeutic benefits of curcumin in depression or anxiety induced by chronic diseases: a systematic review of mechanistic and clinical evidence.Frontiers in pharmacology · 2025Pooled it
- Depression and the risk of myocardial infarction: evidence from a cross-sectional analysis of NHANES 2005-2020.Annals of general psychiatry · 2026Article
- Health Insurance as a Moderator of Cardiovascular Risk Among Adults with Depression: A Cross-Sectional and Geographic Analysis Using BRFSS 2019-2023 Data.Healthcare (Basel, Switzerland) · 2026Article
- Long-term social isolation during adolescence exacerbated cardiac dysfunction after myocardial infarction.Translational psychiatry · 2026Article
- Treating myocardial infarction combined with depression via regulating M1/TNF-α/TNFR1/NF-κB.Biochemistry and biophysics reports · 2026Article
- New insights into the gut-heart axis: microbial metabolite biomarkers, multi-omics, and engineered bacterial delivery systems.Frontiers in microbiology · 2026Review
- Gut microbiota dysbiosis promotes coronary heart disease comorbid with depression through lipopolysaccharides and Toll-like receptor 4.BMC microbiology · 2025Article
- CD38 connects the heart and brain.Translational psychiatry · 2025Review
- Depressive and Anxiety Symptoms, Defense Mechanisms, and Mentalized Affectivity in Individuals with Myocardial Infarction: An Empirical Investigation.Behavioral sciences (Basel, Switzerland) · 2025Article
- Efficacy and safety of Shugan Jieyu Capsule in the treatment of depressive state after acute coronary syndrome: study protocol for a multicenter randomized controlled trial.Frontiers in psychiatry · 2025Article
- Extracellular Vesicles: A Crucial Player in the Intestinal Microenvironment and Beyond.International journal of molecular sciences · 2024Review
- Investigation of the shared molecular mechanisms and hub genes between myocardial infarction and depression.Frontiers in cardiovascular medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
Depression resulted as an important factor associated with the myocardial infarction (MI) prognosis. Patients with MI also have a higher risk for developing depression. Although the issue of depression after MI has become a matter of clinical concern, the molecular mechanism underlying depression after MI remains unclear, whereby several strategies suggested have not got ideal effects, such as selective serotonin reuptake inhibitors. In this review, we summarized and discussed the occurrence mechanism of depression after MI, such as 5-hydroxytryptamine (5-HT) dysfunction, altered hypothalamus-pituitary-adrenal (HPA) axis function, gut microbiota imbalance, exosomal signal transduction, and inflammation. In addition, we offered a succinct overview of treatment, as well as some promising molecules especially from natural products for the treatment of depression after MI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.